291P - P53 can predict outcome after taxene-based adjuvant chemotherapy in patients with early breast cancer

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Translational Research
Breast Cancer
Basic Principles in the Management and Treatment (of cancer)
Presenter Ho Jung An
Authors H.J. An1, H. Lee2, G. Gong2, K. Kim1, J. Ahn1, K.H. Jung1, J.E. Kim1, B.H. Son3, S. Ahn3, S. Kim4
  • 1Department Of Oncology, Asan Medical Center, Seoul/KR
  • 2Pathology, Asan Medical Center, Seoul/KR
  • 3Surgery, Asan Medical Center, Seoul/KR
  • 4Asan Medical Center, Seoul/KR



Taxene-based adjuvant chemotherapy is widely accepted in lymph node (LN)-positive breast cancer, but few biomarkers exist to predict clinical outcomes. We prospectively investigate the role of potential biomarkers in LN-positive breast cancer population homogenously treated with docetaxel-containing adjuvant chemotherapy.


From 2007 to 2008, 218 patients with LN-positive breast cancer who received adjuvant chemotherapy (4 cycles of adriamycin 60 mg/m2 and cyclophosphamide 600 mg/m2 followed by 4 cycles of docetaxel 100 mg/m2) were enrolled in this analysis. Immunohistochemical stainings for ER, PR, p53, topoisomerase-IIα, �-III tubulin, Tau, CYP3A4 and Her2/neu were performed in formalin-fixed, paraffin-embedded tissue section and their relationships with prognosis were investigated.


With a median follow-up of 58.3 months (range, 10.9-62.9), p53 and topoisomerase-IIα over-expression were associated with poor relapse-free survival (RFS) and overall survival (OS) along with tumor size >2 cm, number of positive LN (≥4), high tumor grade (G3), and negativity of hormone receptor in univariate analyses. However, in multivariate analyses, number of positive LN ≥4 (HR = 2.47; 95% CI, 1.07-5.74; p = 0.035), high tumor grade (HR = 2.76; 95% CI, 1.08-7.09, p = 0.034), and over-expression of p53 (HR = 6.55; 95% CI, 2.40-17.85, p < 0.001) were independent poor prognostic factors for RFS. And p53 over-expression was also related to poor OS (HR = 3.93; 95% CI, 1.04-14.81, p = 0.044). Patients with high p53 expression (≥10% of positive cells) tended to have tumors with large size, higher grade and lower hormone receptor positivity compared to those of low p53 expression.


p53 over-expression along with number of positive LN and tumor grade was found to be useful biomarker to predict poor outcomes in patients with LN-positive breast cancer receiving docetaxel-based adjuvant chemotherapy.


All authors have declared no conflicts of interest.